159 related articles for article (PubMed ID: 23292002)
21. Binding of HTm4 to cyclin-dependent kinase (Cdk)-associated phosphatase (KAP).Cdk2.cyclin A complex enhances the phosphatase activity of KAP, dissociates cyclin A, and facilitates KAP dephosphorylation of Cdk2.
Chinami M; Yano Y; Yang X; Salahuddin S; Moriyama K; Shiroishi M; Turner H; Shirakawa T; Adra CN
J Biol Chem; 2005 Apr; 280(17):17235-42. PubMed ID: 15671017
[TBL] [Abstract][Full Text] [Related]
22. Over-expression of cathepsin B in hepatocellular carcinomas predicts poor prognosis of HCC patients.
Ruan J; Zheng H; Rong X; Rong X; Zhang J; Fang W; Zhao P; Luo R
Mol Cancer; 2016 Feb; 15():17. PubMed ID: 26896959
[TBL] [Abstract][Full Text] [Related]
23. MIF4G domain containing protein regulates cell cycle and hepatic carcinogenesis by antagonizing CDK2-dependent p27 stability.
Wan C; Hou S; Ni R; Lv L; Ding Z; Huang X; Hang Q; He S; Wang Y; Cheng C; Gu XX; Xu G; Shen A
Oncogene; 2015 Jan; 34(2):237-45. PubMed ID: 24336329
[TBL] [Abstract][Full Text] [Related]
24. Nek7 is overexpressed in hepatocellular carcinoma and promotes hepatocellular carcinoma cell proliferation in vitro and in vivo.
Zhou L; Wang Z; Xu X; Wan Y; Qu K; Fan H; Chen Q; Sun X; Liu C
Oncotarget; 2016 Apr; 7(14):18620-30. PubMed ID: 26921196
[TBL] [Abstract][Full Text] [Related]
25. The activation of MEK/ERK signaling pathway by bone morphogenetic protein 4 to increase hepatocellular carcinoma cell proliferation and migration.
Chiu CY; Kuo KK; Kuo TL; Lee KT; Cheng KH
Mol Cancer Res; 2012 Mar; 10(3):415-27. PubMed ID: 22241220
[TBL] [Abstract][Full Text] [Related]
26. Rho-kinase 2 is frequently overexpressed in hepatocellular carcinoma and involved in tumor invasion.
Wong CC; Wong CM; Tung EK; Man K; Ng IO
Hepatology; 2009 May; 49(5):1583-94. PubMed ID: 19205033
[TBL] [Abstract][Full Text] [Related]
27. Discovery of vanoxerine dihydrochloride as a CDK2/4/6 triple-inhibitor for the treatment of human hepatocellular carcinoma.
Zhu Y; Ke KB; Xia ZK; Li HJ; Su R; Dong C; Zhou FM; Wang L; Chen R; Wu SG; Zhao H; Gu P; Leung KS; Wong MH; Lu G; Zhang JY; Jiang BH; Qiu JG; Shi XN; Lin MC
Mol Med; 2021 Feb; 27(1):15. PubMed ID: 33579185
[TBL] [Abstract][Full Text] [Related]
28. Downregulation of PRAME Suppresses Proliferation and Promotes Apoptosis in Hepatocellular Carcinoma Through the Activation of P53 Mediated Pathway.
Zhu H; Wang J; Yin J; Lu B; Yang Q; Wan Y; Jia C
Cell Physiol Biochem; 2018; 45(3):1121-1135. PubMed ID: 29439259
[TBL] [Abstract][Full Text] [Related]
29. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
[TBL] [Abstract][Full Text] [Related]
30. In Silico Identification and In Vitro and In Vivo Validation of Anti-Psychotic Drug Fluspirilene as a Potential CDK2 Inhibitor and a Candidate Anti-Cancer Drug.
Shi XN; Li H; Yao H; Liu X; Li L; Leung KS; Kung HF; Lu D; Wong MH; Lin MC
PLoS One; 2015; 10(7):e0132072. PubMed ID: 26147897
[TBL] [Abstract][Full Text] [Related]
31. TRIM66 confers tumorigenicity of hepatocellular carcinoma cells by regulating GSK-3β-dependent Wnt/β-catenin signaling.
Fan W; Du F; Liu X
Eur J Pharmacol; 2019 May; 850():109-117. PubMed ID: 30710548
[TBL] [Abstract][Full Text] [Related]
32. RNA interference against cancer/testis genes identifies dual specificity phosphatase 21 as a potential therapeutic target in human hepatocellular carcinoma.
Deng Q; Li KY; Chen H; Dai JH; Zhai YY; Wang Q; Li N; Wang YP; Han ZG
Hepatology; 2014 Feb; 59(2):518-30. PubMed ID: 23929653
[TBL] [Abstract][Full Text] [Related]
33. Golgi phosphoprotein 3 (GOLPH3) promotes hepatocellular carcinoma progression by activating mTOR signaling pathway.
Liu H; Wang X; Feng B; Tang L; Li W; Zheng X; Liu Y; Peng Y; Zheng G; He Q
BMC Cancer; 2018 Jun; 18(1):661. PubMed ID: 29914442
[TBL] [Abstract][Full Text] [Related]
34. Hydrazinocurcumin and 5-fluorouracil enhance apoptosis and restrain tumorigenicity of HepG2 cells via disrupting the PTEN-mediated PI3K/Akt signaling pathway.
Zhou Y; Zhang M; Zhang Z; Jia Y; Zhang C; Peng L
Biomed Pharmacother; 2020 Sep; 129():109851. PubMed ID: 32559627
[TBL] [Abstract][Full Text] [Related]
35. Targeted disruption of S100P suppresses tumor cell growth by down-regulation of cyclin D1 and CDK2 in human hepatocellular carcinoma.
Kim JK; Jung KH; Noh JH; Eun JW; Bae HJ; Xie HJ; Ahn YM; Ryu JC; Park WS; Lee JY; Nam SW
Int J Oncol; 2009 Dec; 35(6):1257-64. PubMed ID: 19885547
[TBL] [Abstract][Full Text] [Related]
36. FAM9C plays an anti-apoptotic role through activation of the PI3K/Akt pathway in human hepatocellular carcinoma.
Zhou JD; Shen F; Ji JS; Zheng K; Huang M; Wu JC
Oncol Rep; 2013 Sep; 30(3):1275-84. PubMed ID: 23836295
[TBL] [Abstract][Full Text] [Related]
37. CUL4A facilitates hepatocarcinogenesis by promoting cell cycle progression and epithelial-mesenchymal transition.
Pan Y; Wang B; Yang X; Bai F; Xu Q; Li X; Gao L; Ma C; Liang X
Sci Rep; 2015 Nov; 5():17006. PubMed ID: 26593394
[TBL] [Abstract][Full Text] [Related]
38. Early growth response 3 inhibits growth of hepatocellular carcinoma cells via upregulation of Fas ligand.
Zhang S; Xia C; Xu C; Liu J; Zhu H; Yang Y; Xu F; Zhao J; Chang Y; Zhao Q
Int J Oncol; 2017 Mar; 50(3):805-814. PubMed ID: 28098878
[TBL] [Abstract][Full Text] [Related]
39. Obg-like ATPase 1 (OLA1) overexpression predicts poor prognosis and promotes tumor progression by regulating P21/CDK2 in hepatocellular carcinoma.
Huang S; Zhang C; Sun C; Hou Y; Zhang Y; Tam NL; Wang Z; Yu J; Huang B; Zhuang H; Zhou Z; Ma Z; Sun Z; He X; Zhou Q; Hou B; Wu L
Aging (Albany NY); 2020 Feb; 12(3):3025-3041. PubMed ID: 32045367
[TBL] [Abstract][Full Text] [Related]
40. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
He C; Dong X; Zhai B; Jiang X; Dong D; Li B; Jiang H; Xu S; Sun X
Oncotarget; 2015 Oct; 6(30):28867-81. PubMed ID: 26311740
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
